A NOVEL THERAPEUTIC WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY

一种具有泛抗性假单胞菌和伯克霍尔德氏菌活性的新型治疗药物

• 批准号: 10710591
• 负责人: RYAN CIRZ
• 金额: $ 479.89万
• 依托单位: REVAGENIX, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-22 至 2024-03-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10710591
• 关键词: Advanced Development; Bacterial Drug Resistance; Burkholderia; Categories; Chemistry; Clinical; Development; Emerging Communicable Diseases; National Institute of Allergy and Infectious Disease; Pathway interactions; Pseudomonas; Pseudomonas aeruginosa; Resistance; efficacy evaluation; novel therapeutics; pre-clinical; priority pathogen; product development; research and development; safety assessment; therapeutic candidate; therapeutic development

To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

支持NIAID A、B和C类优先病原体或新发传染病的有前景候选治疗药物的高级开发。支持的研发活动将使候选治疗产品通过产品开发途径取得进展，包括临床前和IND使能开发活动、化学优化/开发、GMP生产以及临床安全性和有效性评估。